Business Description
Alnylam Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US02043Q1076
Description
Financial Strength
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 1.82 | |||||
Equity-to-Asset | -0.06 | |||||
Debt-to-Equity | -5.93 | |||||
Debt-to-EBITDA | -12.91 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 1.26 | |||||
Beneish M-Score | -2.41 | |||||
WACC vs ROIC |
Growth Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 50.6 | |||||
3-Year EBITDA Growth Rate | 34.2 | |||||
3-Year EPS without NRI Growth Rate | 28.3 | |||||
Future 3-5Y Total Revenue Growth Rate | 14.7 |
Momentum Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 80.39 | |||||
9-Day RSI | 68.06 | |||||
14-Day RSI | 60.55 | |||||
6-1 Month Momentum % | -11.49 | |||||
12-1 Month Momentum % | -23.22 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 3.17 | |||||
Quick Ratio | 3.07 | |||||
Cash Ratio | 2.52 | |||||
Days Inventory | 116.08 | |||||
Days Sales Outstanding | 51.55 | |||||
Days Payable | 74.81 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -2.6 | |||||
Shareholder Yield % | -0.36 |
Profitability Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 83.95 | |||||
Operating Margin % | -8.78 | |||||
Net Margin % | -16.58 | |||||
FCF Margin % | 6.65 | |||||
ROA % | -9.08 | |||||
ROIC % | -17.46 | |||||
ROC (Joel Greenblatt) % | -27.03 | |||||
ROCE % | -7.06 |
GF Value Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 9.71 | |||||
Price-to-Free-Cash-Flow | 169.82 | |||||
Price-to-Operating-Cash-Flow | 110.3 | |||||
EV-to-EBIT | -92.27 | |||||
EV-to-Forward-EBIT | -44.18 | |||||
EV-to-EBITDA | -180.57 | |||||
EV-to-Forward-EBITDA | -49.4 | |||||
EV-to-Revenue | 9.08 | |||||
EV-to-Forward-Revenue | 9.6 | |||||
EV-to-FCF | 142.37 | |||||
Price-to-Median-PS-Value | 0.11 | |||||
Earnings Yield (Greenblatt) % | -1.08 | |||||
FCF Yield % | 0.66 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Alnylam Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 1,855.464 | ||
EPS (TTM) (€) | -2.449 | ||
Beta | -0.1 | ||
Volatility % | 30.61 | ||
14-Day RSI | 60.55 | ||
14-Day ATR (€) | 2.602309 | ||
20-Day SMA (€) | 137.9975 | ||
12-1 Month Momentum % | -23.22 | ||
52-Week Range (€) | 131.55 - 195.8 | ||
Shares Outstanding (Mil) | 126.49 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 6 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Alnylam Pharmaceuticals Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Alnylam Pharmaceuticals Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Alnylam Pharmaceuticals Inc Frequently Asked Questions
What is Alnylam Pharmaceuticals Inc(STU:DUL)'s stock price today?
When is next earnings date of Alnylam Pharmaceuticals Inc(STU:DUL)?
Does Alnylam Pharmaceuticals Inc(STU:DUL) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |